Abstract: The present application describes modulators of MIP-1? of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, T, W, R1, R4, R5, R5a and R5b are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.
Type:
Grant
Filed:
January 23, 2007
Date of Patent:
November 10, 2009
Assignee:
Bristol-Myers Squibb Company
Inventors:
Percy H. Carter, Cullen L. Cavallaro, George V. De Lucca
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of Trk receptors such as TrkA, TrkB and TrkC thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
Abstract: The present application describes substituted piperidinyl modulators of MIP-1? or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.
Type:
Grant
Filed:
January 23, 2007
Date of Patent:
October 13, 2009
Assignee:
Bristol-Myers Squibb Company
Inventors:
Percy H. Carter, Cullen L. Cavallaro, John V. Duncia, Daniel S. Gardner, John Hynes, Rui-Qin Liu, Joseph B. Santella, Dharmpal S. Dodd
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
February 8, 2006
Date of Patent:
June 16, 2009
Assignee:
Bristol-Myers Squibb Company
Inventors:
Robert M. Borzilleri, Rajeev S. Bhide, John S. Tokarski, Peter Zheng, Ligang Qian, Zhen-Wei Cai
Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
Type:
Grant
Filed:
July 5, 2007
Date of Patent:
May 19, 2009
Assignee:
Bristol-Myers Squibb Company
Inventors:
Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of such as TrkA, TrkB, TrkC, Jak2, Jak3 and CK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
Type:
Grant
Filed:
August 8, 2007
Date of Patent:
May 12, 2009
Assignee:
Bristol-Myers Squibb Company
Inventors:
Brian E. Fink, Ping Chen, Ashok Vinayak Purandare, Honghe Wan
Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
August 2, 2007
Date of Patent:
April 21, 2009
Assignee:
Bristol-Myers Squibb Company
Inventors:
Rajeev S. Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa, Louis Lombardo, Jeffrey Robl
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of Trk receptors such as TrkA, TrkB, TrkC or Flt-3 thereby making them useful as antiproliferative agents.
Type:
Grant
Filed:
November 16, 2006
Date of Patent:
April 7, 2009
Assignee:
Bristol-Myers Squibb Company
Inventors:
Ping Chen, Yufen Zhao, Brian E. Fink, Soong-Hoon Kim
Abstract: Leptomycin-type compounds according to Formula I wherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.
Type:
Grant
Filed:
June 1, 2005
Date of Patent:
November 4, 2008
Assignee:
Kosan Biosciences, Incorporated
Inventors:
Steven Dong, Daniel V. Santi, David C. Myles, Brian Hearn
Abstract: The present invention is directed to intermediates that are useful for preparing pyrrolotriazines, and processes for preparing such intermediates.
Type:
Grant
Filed:
June 24, 2005
Date of Patent:
October 7, 2008
Assignee:
Bristol-Meyers Squibb Company
Inventors:
Gerard Crispino, Stephanie Barbosa, Junying Fan, Zhen-wei Cai
Abstract: The invention relates to a process for the enzymatic, stereoselective reduction of ketone compounds to provide chiral alcohols, for example the compound of formula Ib:
Type:
Grant
Filed:
May 31, 2006
Date of Patent:
July 1, 2008
Assignee:
Bristol-Myers Squibb Company
Inventors:
Ramesh N. Patel, Linda Nga Hoong Chu, Robert M. Johnson, Zhiwei Guo, Yijun Chen, Steven L. Goldberg, Ronald L. Hanson, Animesh Goswami, Kishta Katipally
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
March 27, 2006
Date of Patent:
April 15, 2008
Assignee:
Bristol-Myers Squibb Company
Inventors:
Ashvinikumar V. Gavai, Ping Chen, Yufen Zhao
Abstract: The present invention provides, inter alia, triphenylethylene derivatives, such as, 3-{4-[6-(3-Methoxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid, as selective estrogen receptor modulators. Also provided are methods for treating estrogen stimulated diseases in mammals including, but not limited to, for example, breast, uterine, ovarian, prostate and colon cancer; osteoporosis; endometriosis; uterine fibroid; Alzheimer's disease; macular degeneration; urinary incontinence; and type II diabetes, as well as, pharmaceutical compositions comprising at least one compound of the present invention.
Type:
Grant
Filed:
June 15, 2005
Date of Patent:
January 29, 2008
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Robert F. Kaltenbach, Simon P. Robinson, George L. Trainor
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
June 26, 2006
Date of Patent:
November 20, 2007
Assignee:
Bristol-Myers Squibb Company
Inventors:
Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Ping Chen, Harold Mastalerz, Derek J. Norris, John S. Tokarski, Yufen Zhao, Wen-Ching Han
Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
January 13, 2005
Date of Patent:
September 4, 2007
Assignee:
Bristol-Myers Squibb Company
Inventors:
Rajeev S. Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa, Louis Lombardo, Jeffrey Robl
Abstract: The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula (I): that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and their regulatory subunits know as cyclins A-G. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.
Type:
Grant
Filed:
February 24, 2005
Date of Patent:
July 31, 2007
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
David A. Nugiel, David J. Carini, Susan V. Di Meo, Anup P. Vidwans, Eddy Yue
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Type:
Grant
Filed:
February 2, 2006
Date of Patent:
July 17, 2007
Assignee:
Bristol-Myers Squibb Company
Inventors:
John T. Hunt, Rajeev S. Bhide, Robert Michael Borzilleri, Ligang Qian
Abstract: Described herein is at least one pyrrolo[1,2-f][1,2,4]triazine-2,4(1H,3H)-dione, which is an intermediates useful in preparing 2,4-disubstituted pyrrolotriazine compounds, and at least one method for making such intermediate.
Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
Type:
Grant
Filed:
November 30, 2005
Date of Patent:
May 29, 2007
Assignee:
Bristol-Myers Squibb Company
Inventors:
Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy